Key facts
- It has raised $103.2M; the latest was Later Stage VC ($20.0M) in Oct 2024.
- Notable investors include Pfizer Ventures, Bristol-Myers Squibb, Takeda Ventures, AbbVie, Elm Street Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for EvolveImmune Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for EvolveImmune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EvolveImmune Therapeutics
Developer of novel immunotherapies designed to provide treatments for unmet needs in oncology and autoimmune diseases. The company's immunotherapies are building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types by leveraging its proprietary in vivo target discovery platform, enabling doctors and physicians to provide better treatments to patients with autoimmune and various other diseases.
- Sector
- Healthcare
- HQ
- Branford, CT, United States
- Founded
- 2019
- Employees
- 53
- Website
- evolveimmune.com/
- Ownership
- Privately Held (backing)
EvolveImmune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EvolveImmune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EvolveImmune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.